While the FCGR2A wild‐type genotype was associated with better OS and PFS, this study's results were of greater magnitude for OS, consistent with our previous findings in CO.17,20 and with several large studies of anti‐EGFR mAbs for wild‐type KRAS colorectal cancer, such as the FIRE‐3 and the PEAK trials.31, 32 Although OS can be confounded by post‐trial treatments, it is less likely to be affected by pre‐trial confounders, given the randomized nature of these trials. The gene discussed is KRAS; the disease is colorectal cancer.